Agenus Inc. positions itself as an innovative clinical-stage biotech in immuno-oncology, anchored by proprietary antibody platforms and a saponin-based vaccine adjuvant technology. Despite a near 50% revenue upswing in fiscal 2025, persistent operating losses and substantial cash burn underscore ongoing financial pressures exacerbated by the recent divestment of in-house manufacturing facilities. The company faces significant execution risks from reliance on third-party contract manufacturing alongside regulatory and market acceptance uncertainties typical in novel oncology treatments. Pending securities litigation adds an additional layer of risk amid pivotal late-stage development milestones. Investors should monitor clinical trial readouts, regulatory filings, capital-raising, and partnership activities as critical inflection points.